Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 15/20 | 0.66 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.56 |
| ▸ | NCS1 | P62166 | 1/20 | 0.56 |
| ▸ | SCD | O00767 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431238 | 0.95 | CASR (0.65) | CASRCSNK1DNCS1SCDPOLB | |
| SCHEMBL2430770 | 0.93 | CASR (0.69) | CASRCSNK1DNCS1POLB | |
| SCHEMBL4038321 | 0.91 | CASR (0.65) | CASRCSNK1DNCS1SCD | |
| SCHEMBL2429969 | 0.89 | CASR (0.68) | CASRCSNK1DNCS1SCD | |
| SCHEMBL2432067 | 0.88 | CASR (0.69) | CASRCSNK1DNCS1 | |
| SCHEMBL2435907 | 0.88 | CASR (0.64) | CASRCSNK1DNCS1POLB | |
| SCHEMBL2430407 | 0.88 | CASR (0.66) | CASRCSNK1DNCS1POLB | |
| SCHEMBL3644521 | 0.87 | CASR (0.68) | CASRCSNK1DNCS1 | |
| SCHEMBL4362893 | 0.87 | CASR (0.68) | CASRCSNK1DNCS1 | |
| SCHEMBL4038262 | 0.87 | CASR (0.65) | CASRCSNK1DNCS1SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041103-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | Galapagos SAS (FR) | 2009-04-01 | — | — | EP | claimed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | claimed |
| WO-2008006625-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SAS (FR) | 2008-01-17 | — | — | WO | claimed |
| EP-2366698-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | Galapagos SAS (FR) | 2011-09-21 | — | — | EP | disclosed |
| EP-2041103-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | Galapagos SAS (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
| WO-2008006625-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SAS (FR) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006625-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SAS (FR) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | UTS2R, CASR, GPR17 | CASR 2/4885CSNK1D 3784/4885NCS1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.